Burcon NutraScience Corporation (BUR)

2.55 +0.00  +0.00%  May 17, 8:00PM
Add to Watchlists Create an Alert

Burcon NutraScience Corporation R&D Expense Quarterly:

0.5752M for Dec. 31, 2012
View Full Chart

Burcon NutraScience Corporation R&D Expense Quarterly Chart

    Burcon NutraScience Corporation Historical R&D Expense Quarterly Data

    Pro Data Export
    Dates:  to
    Viewing 1 of 1   First  Previous First    Next  Last   Last

    There is no data for the selected date range.

    Data for this Date Range  
    Dec. 31, 2012 0.5752M
    Sept. 30, 2012 0.1228M
    June 30, 2012 0.0565M
    March 31, 2012
    Dec. 31, 2011 0.4387M
    Sept. 30, 2011 0.0486M
    June 30, 2011 0.0286M
    March 31, 2011
    Dec. 31, 2010 0.0912M
    Sept. 30, 2010 0.6768M
    June 30, 2010 0.7743M
    March 31, 2010 0.8131M
    Dec. 31, 2009 0.4473M
    Sept. 30, 2009 0.3872M
    June 30, 2009 0.406M
    March 31, 2009 0.5642M
    Dec. 31, 2008 0.3373M
    Sept. 30, 2008 0.4619M
    June 30, 2008 0.4809M
       
    March 31, 2008 Go Pro
    Dec. 31, 2007 Go Pro
    Sept. 30, 2007 Go Pro
    June 30, 2007 Go Pro
    March 31, 2007 Go Pro
    Dec. 31, 2006 Go Pro
    Sept. 30, 2006 Go Pro
    June 30, 2006 Go Pro
    March 31, 2006 Go Pro
    Dec. 31, 2005 Go Pro
    Sept. 30, 2005 Go Pro
    June 30, 2005 Go Pro
    March 31, 2005 Go Pro
    Dec. 31, 2004 Go Pro
    Sept. 30, 2004 Go Pro
    June 30, 2004 Go Pro
    March 31, 2004 Go Pro
    Dec. 31, 2003 Go Pro
    Sept. 30, 2003 Go Pro

    About R&D Expense

    R&D expenses are a line item from many companies' income statements.

    R&D expense (short for research and development expense) is essentially the amount of money that a company spends to develop new products and services each year. For example, if a pharmaceutical firm hires research scientists to develop new drugs, the salaries of these researchers will generally be expensed in the R&D expense category.

    Like marketing expenses, but unlike capital expenditures, R&D expenses are subtracted from revenues every year directly. Therefore, accountants treat R&D spending as an expense rather than as an investment, though there is continuous debate over whether this is the correct classification.

    An investor looking at companies with large R&D expenditures should think hard about whether a single company's R&D spending is an expense (like buying rubber to produce tires) or whether it is an investment (like buying machinery to produce tires more efficiently). Determining the answer to that question can have a large impact on how the company is valued.
    Learn More

    Get data for

    BUR R&D Expense Quarterly Benchmarks

    Companies
    ARCA biopharma 0.191M
    Bioline Rx 5.352M
    Sangamo BioSciences 9.282M

    BUR R&D Expense Quarterly Rankings

    Overall 81st percentile
    1372 of 7590
    Sector 35th percentile
    420 of 651 in Healthcare
    Industry 22nd percentile
    184 of 237 in Biotechnology

    BUR R&D Expense Quarterly Range, Past 5 Years

    Minimum 0.0286M Jun 2011
    Maximum 0.8131M Mar 2010
    Average 0.3948M